Have a feature idea you'd love to see implemented?
Let us know!
PHAT Phathom Pharmaceuticals Inc
Price (delayed)
$9.45
Market cap
$646.17M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.75
Enterprise value
$807.42M
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States,
Highlights
Phathom Pharmaceuticals's gross profit has soared by 176% from the previous quarter
The revenue has soared by 165% from the previous quarter
PHAT's debt has surged by 123% year-on-year
PHAT's net income has dropped by 92% year-on-year and by 14% since the previous quarter
Key stats
What are the main financial stats of PHAT
Market
Valuations
Earnings
Shares outstanding
68.38M
Market cap
$646.17M
Enterprise value
$807.42M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
23.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.74
Revenue
$26.27M
EBIT
-$273M
EBITDA
-$272.21M
Free cash flow
-$247.72M
Per share
Balance sheet
Liquidity
EPS
-$5.75
Free cash flow per share
-$3.83
Book value per share
-$3.14
Revenue per share
$0.41
TBVPS
$5.99
Total assets
$387.04M
Total liabilities
$574.16M
Debt
$498.8M
Equity
-$187.11M
Working capital
$308.53M
Debt to equity
-2.67
Current ratio
5.73
Quick ratio
5.49
Net debt/EBITDA
-0.59
Margins
Efficiency
Dividend
EBITDA margin
-1,036.2%
Gross margin
83.5%
Net margin
-1,292.1%
Operating margin
-1,096%
Return on assets
-91.9%
Return on equity
N/A
Return on invested capital
-59.3%
Return on capital employed
-84.8%
Return on sales
-1,039.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PHAT stock price
How has the Phathom Pharmaceuticals stock price performed over time
Intraday
8.25%
1 week
3.96%
1 month
-39.11%
1 year
31.07%
YTD
3.5%
QTD
-47.73%
Financial performance
How have Phathom Pharmaceuticals's revenue and profit performed over time
Revenue
$26.27M
Gross profit
$21.95M
Operating income
-$287.93M
Net income
-$339.45M
Gross margin
83.5%
Net margin
-1,292.1%
Phathom Pharmaceuticals's gross profit has soared by 176% from the previous quarter
The revenue has soared by 165% from the previous quarter
The company's operating income has shrunk by 100% YoY and by 14% QoQ
PHAT's net income has dropped by 92% year-on-year and by 14% since the previous quarter
Growth
What is Phathom Pharmaceuticals's growth rate over time
Valuation
What is Phathom Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
23.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.74
The EPS has dropped by 51% year-on-year and by 11% since the previous quarter
The equity rose by 20% QoQ
The revenue has soared by 165% from the previous quarter
The price to sales (P/S) is 91% lower than the last 4 quarters average of 257.7
Efficiency
How efficient is Phathom Pharmaceuticals business performance
The ROS has soared by 57% since the previous quarter
The ROIC has grown by 11% YoY
Phathom Pharmaceuticals's ROA has decreased by 5% YoY and by 2.6% from the previous quarter
Dividends
What is PHAT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PHAT.
Financial health
How did Phathom Pharmaceuticals financials performed over time
The total assets is 33% smaller than the total liabilities
The total liabilities has soared by 125% year-on-year and by 3.8% since the previous quarter
The total assets has surged by 63% year-on-year and by 21% since the previous quarter
PHAT's debt has surged by 123% year-on-year
The debt to equity has surged by 79% year-on-year but it has declined by 26% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.